Raymond James Reaffirms Their Hold Rating on Cytokinetics (CYTK)

Raymond James analyst maintained a Hold rating on Cytokinetics yesterday. The company’s shares closed yesterday at $74.84.

Claim 55% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Cytokinetics has an analyst consensus of Strong Buy, with a price target consensus of $98.06, a 31.03% upside from current levels. In a report released on April 30, Bank of America Securities also maintained a Hold rating on the stock with a $67.00 price target.

Based on Cytokinetics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $17.76 million and a GAAP net loss of $183.03 million. In comparison, last year the company earned a revenue of $16.93 million and had a GAAP net loss of $150.02 million

Based on the recent corporate insider activity of 156 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CYTK in relation to earlier this year. Earlier this month, John Henderson, a Director at CYTK sold 20,000.00 shares for a total of $1,519,400.00.